The combination of TAS-102 and bevacizumab as the third-line chemotherapy for metastatic colorectal cancer (TAS-CC3 Study).

被引：0
|
作者：
Kosugi, Chihiro
Kamiyama, Hirohiko
Yoshida, Yoichiro
Yoshida, Hiroshi
Ishibashi, Keiichiro
Ihara, Keisuke
Takahashi, Makoto
Kuramochi, Hidekazu
Sonoda, Hiromichi
Yoshimatsu, Kazuhiko
Fukazawa, Atsuko
Matsuda, Akihisa
Yamaguchi, Satoru
Ishida, Hideyuki
Hasegawa, Suguru
Yamada, Takeshi
Narushima, Kazuo
Shuto, Kiyohiko
Sakamoto, Kazuhiro
Koda, Keiji
机构：
[1] Teikyo Univ, Chiba Med Ctr, Ichihara, Chiba, Japan
[2] Juntendo Univ, Sch Med, Dept Coloproctol Surg, Bunkyo Ku, Tokyo, Japan
[3] Fukuoka Univ, Fukuoka, Fukuoka, Japan
[4] Nippon Med Univ, Dept Gastroenterol Surg, Tokyo, Japan
[5] Saitama Med Univ, Saitama, Japan
[6] Dokkyo Univ, Dept Surg Oncol, Sch Med, Mibu, Tochigi, Japan
[7] 3-1-3 Hongo,Bunkyo Ku, Tokyo, Japan
[8] Tokyo Womens Med Univ, Yachiyo Med Ctr, Yachiyoshi Chiba, Japan
[9] Shiga Univ Med Sci, Dept Surg, Otsu, Shiga, Japan
[10] Saiseikai Kurihashi Hosp, Dept Surg, Kuki, Saitama, Japan
[11] Iwata City Hosp, Dept Surg, Iwata, Shizuoka, Japan
[12] Chiba Hokusoh Hosp, Nippon Med Sch, Dept Surg, Chiba, Japan
[13] Fukuoka Univ, Sch Med, Dept Gastroenterol Surg, Fukuoka, Fukuoka, Japan
[14] Nippon Med Sch, Dept Digest Surg, Tokyo, Japan
[15] Teikyo Univ, Chiba Med Ctr, Ichihara, Chiba, Japan
[16] Juntendo Univ, Sch Med, Dept Coloproctol Surg, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.614
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
614
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study
    Yoshida, Yoichiro
    Yamada, Takeshi
    Kamiyama, Hirohiko
    Kosugi, Chihiro
    Ishibashi, Keiichiro
    Yoshida, Hiroshi
    Ishida, Hideyuki
    Yamaguchi, Satoru
    Kuramochi, Hidekazu
    Fukazawa, Atsuko
    Sonoda, Hiromichi
    Yoshimatsu, Kazuhiko
    Matsuda, Akihisa
    Hasegawa, Suguru
    Sakamoto, Kazuhiro
    Otsuka, Toshiaki
    Koda, Keiji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (01) : 111 - 117
  • [2] Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study
    Yoichiro Yoshida
    Takeshi Yamada
    Hirohiko Kamiyama
    Chihiro Kosugi
    Keiichiro Ishibashi
    Hiroshi Yoshida
    Hideyuki Ishida
    Satoru Yamaguchi
    Hidekazu Kuramochi
    Atsuko Fukazawa
    Hiromichi Sonoda
    Kazuhiko Yoshimatsu
    Akihisa Matsuda
    Suguru Hasegawa
    Kazuhiro Sakamoto
    Toshiaki Otsuka
    Keiji Koda
    International Journal of Clinical Oncology, 2021, 26 : 111 - 117
  • [3] The combination of TAS-102 and bevacizumab as the third line chemotherapy for metastatic colorectal cancer (TAS-CC3 Study)
    Kamiyama, H.
    Yoshida, Y.
    Yoshida, H.
    Kosugi, C.
    Ishibashi, K.
    Ihara, K.
    Takahashi, M.
    Kuramochi, H.
    Fukazawa, A.
    Sonoda, H.
    Yoshimatsu, K.
    Matsuda, A.
    Yamaguchi, S.
    Ishida, H.
    Hasegawa, S.
    Yamada, T.
    Sakamoto, K.
    Koda, K.
    ANNALS OF ONCOLOGY, 2018, 29 : 157 - 157
  • [4] Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer
    Kawahara, Hidejiro
    Mouri, Takashi
    Ishida, Kota
    Matsumoto, Nori
    Akiba, Tadashi
    Yanaga, Katsuhiko
    ANTICANCER RESEARCH, 2018, 38 (04) : 2419 - 2422
  • [5] Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer
    Kawahara, Hidejiro
    Yanaga, Katsuhiko
    CANCER SCIENCE, 2018, 109 : 601 - 601
  • [6] Biweekly TAS-102 and bevacizumab as a third-line chemotherapy for metastatic colorectal cancer: A phase II multicenter clinical trial (TAS-CC4 study)
    Yoshida, Y.
    Yamada, T.
    Matsuoka, H.
    Hirata, K.
    Kuramochi, H.
    Kosugi, C.
    Takahashi, M.
    Fukazawa, A.
    Sonoda, H.
    Matsuda, A.
    Watanabe, T.
    Koizumi, M.
    Aisu, N.
    Hasegawa, S.
    Yoshida, H.
    Sakamoto, K.
    Ishida, H.
    Koda, K.
    ANNALS OF ONCOLOGY, 2019, 30 : 235 - 235
  • [7] Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study)
    Hiroshi Matsuoka
    Takeshi Yamada
    Ryo Ohta
    Yoichiro Yoshida
    Tatsuyuki Watanabe
    Makoto Takahashi
    Chihiro Kosugi
    Atsuko Fukazawa
    Hidekazu Kuramochi
    Akihisa Matsuda
    Hiromichi Sonoda
    Hiroshi Yoshida
    Suguru Hasegawa
    Kazuhiro Sakamoto
    Toshiaki Otsuka
    Keiji Hirata
    Keiji Koda
    International Journal of Clinical Oncology, 2022, 27 : 1859 - 1866
  • [8] Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study)
    Matsuoka, Hiroshi
    Yamada, Takeshi
    Ohta, Ryo
    Yoshida, Yoichiro
    Watanabe, Tatsuyuki
    Takahashi, Makoto
    Kosugi, Chihiro
    Fukazawa, Atsuko
    Kuramochi, Hidekazu
    Matsuda, Akihisa
    Sonoda, Hiromichi
    Yoshida, Hiroshi
    Hasegawa, Suguru
    Sakamoto, Kazuhiro
    Otsuka, Toshiaki
    Hirata, Keiji
    Koda, Keiji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (12) : 1859 - 1866
  • [9] The pretreatment lymphocyte-to-monocyte ratio (LMR) to predict treatment efficacy and prognosis in metastatic colorectal cancer treated with the combination of TAS-102 and bevacizumab (TAS-CC3 Study)
    Matsuda, Akihisa
    Yoshida, Yoichiro
    Kamiyama, Hirohiko
    Kosugi, Chihiro
    Yoshida, Hiroshi
    Ishibashi, Keiichiro
    Ihara, Keisuke
    Takahashi, Makoto
    Kuramochi, Hidekazu
    Fukazawa, Atsuko
    Sonoda, Hiromichi
    Yoshimatsu, Kazuhiko
    Yamaguchi, Satoru
    Ishida, Hideyuki
    Hasegawa, Suguru
    Yamada, Takeshi
    Sakamoto, Kazuhiro
    Koda, Keiji
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [10] TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
    Liu, Cheng-Jiang
    Hu, Ting
    Shao, Ping
    Chu, Wu-Yang
    Cao, Yu
    Zhang, Feng
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2021, 2021
12345